CRAD B logo

C-Rad AB (publ) Stock Price

OM:CRAD B Community·SEK 1.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

CRAD B Share Price Performance

SEK 36.40
1.10 (3.12%)
SEK 45.00
Fair Value
SEK 36.40
1.10 (3.12%)
19.1% undervalued intrinsic discount
SEK 45.00
Fair Value
Price SEK 36.40
AnalystConsensusTarget SEK 45.00

CRAD B Community Narratives

·
Fair Value SEK 45 19.1% undervalued intrinsic discount

Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

CRAD B logo

CRAD B: New Radiotherapy Partnership Will Support A More Positive Outlook

Fair Value: SEK 45 19.1% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
4 Rewards

C-Rad AB (publ) Key Details

SEK 444.4m

Revenue

SEK 110.0m

Cost of Revenue

SEK 334.4m

Gross Profit

SEK 284.6m

Other Expenses

SEK 49.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
1.48
75.26%
11.22%
0%
View Full Analysis

About CRAD B

Founded
2004
Employees
98
CEO
Tomas Blomquist
WebsiteView website
c-rad.com

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.

Recent CRAD B News & Updates

Analysis Article Jul 21

C-Rad AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

C-Rad AB (publ) ( STO:CRAD B ) just released its latest quarterly results and things are looking bullish. It was...
Narrative Update Jul 20

CRAD B: New Radiotherapy Partnership Will Support A More Positive Outlook

Analysts have raised their price target for C-Rad from SEK 36 to SEK 45, citing updated assumptions about fair value, discount rate, revenue growth and profit margins in their models. What’s in the News for C-Rad C-Rad AB and SeeTreat Pty Ltd announced a partnership focused on more connected, intelligent and patient centric radiotherapy workflows.

Recent updates

No updates